Connor, Clark & Lunn Investment Management (CC&L)
ONCT

Connor, Clark & Lunn Investment Management (CC&L)’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-18
Closed -$52K – 768
2013
Q3 		$52K Buy
18
+3
+20% +$14.9K ﹤0.01% 504
2013
Q2 		$145K Buy
+15
New +$116K ﹤0.01% 490

Other funds holding ONCT

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ONCT Position: Q4 2013 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2013, closing a stake of 18 shares — an estimated $52K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ONCT in Q2 2013 and held it in 2 quarters. The position peaked at $145K in Q2 2013. 58 funds tracked by Wall St. Rank hold ONCT as of Q4 2013.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2013 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 18 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2013, an estimated $52K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Oncternal Therapeutics, Inc. Common Stock position peaked at $145K in Q2 2013.
  • 58 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2013.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2013, filed 13 Feb 2014.